Canada markets close in 1 hour 58 minutes

LLY Jan 2025 520.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
5.47-3.78 (-40.86%)
As of 01:22PM EDT. Market open.
Full screen
Loading interactive chart...
  • Yahoo Finance

    Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024

    Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.

  • Yahoo Finance Video

    Why these analysts are bullish on healthcare stocks

    The healthcare sector has underperformed throughout 2024, but as the first quarter earnings season unfolds, Jefferies Healthcare Services Equity Research Analyst Brian Tanquilut and Grey Ghost Advisors Private Equity Investor Meghan Fitzgerald join Market Domination to discuss how investors should position themselves in this market. Fitzgerald remains bullish on the healthcare sector, believing it still has "a lot of long and important tailwinds." She cites the sector's historical outperformance during market downturns and election years as reasons for her optimism. Fitzgerald anticipates strong earnings from companies with GLP-1 drug portfolios this week, describing it as an "easy beat." Tanquilut notes a "rise in broader healthcare utilization trends," which is now reflected in healthcare insurers' earnings. While there has been weakness in this area, he highlights the "strength in volume" from healthcare providers. However, Tanquilut acknowledges that with consumer spending slowing, consumer-focused healthcare segments, such as drugstores, have experienced pressure. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Angel Smith

  • Yahoo Finance

    How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk

    The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?